Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 20, 2011 Travis Hoium	Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
The Motley Fool November 24, 2006 Brian Lawler	Amylin Gets Past the Formalities Following a formal approval from the EU for Byetta, Amylin can get down to business. Investors, take note.
The Motley Fool April 19, 2004 Ben McClure	Ruminations on R&D Spending on research and development is important. But can it help identify promising investments? It's pretty easy to spot companies that spend a lot of money on R&D. It's another thing to pick companies that translate R&D spending into higher stock prices.
Chemistry World October 26, 2011 Maria Burke	Europe risks being outstripped by R&D rivals EU companies are lagging behind in R&D investment compared with major competitors from the US and some Asian economies, according to the European Commission's 2011 EU Industrial R&D Investment Scoreboard.
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
IndustryWeek November 3, 2009	Benchmarking R&D Top innovators increased their research-and-development spending even as the economy sank, according to the Booz & Co. fifth annual analysis of global innovation spending.
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
IndustryWeek October 20, 2010	Innovation Nation? Manufacturers are more involved than other industries in innovation, but engagement is hardly widespread.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
InternetNews June 15, 2006 Michael Hickins	Open Source Is a Model For Innovation IBM offers consulting help for R&D organizations hoping to have a greater impact on innovation.
IndustryWeek January 1, 2009 Jill Jusko	R&D Spending: By the Numbers While the software industry spends 13.6% on R&D as a percentage of sales, the chemicals and energy sector spends only 1%.
Chemistry World October 21, 2008 Hepeng Jia	OECD urges China to innovate Despite China's impressive investment in research and development, the country lags behind others when it comes to innovation.
IndustryWeek January 31, 2012 Josh Cable	GE Barometer: Executives Believe Innovation and Growth Go Hand-in-Hand However, uncertainty in the global economy is curbing their companies' appetites for risk and making it harder for them to find capital.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Chemistry World September 9, 2014 Hepeng Jia	R&D share for basic research in China dwindles Although China has dramatically increased its science and technology spending in recent years, the proportion of the research budget being spent on basic and applied research is shrinking.
The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
The Motley Fool January 19, 2007 Selena Maranjian	In R&D, China Is No. 2 China passes Japan in research and development spending. What does this mean to investors?
Pharmaceutical Executive October 1, 2011 Daniel Vasella	Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
The Motley Fool March 15, 2007 Chuck Saletta	The American Century Is Over As more R&D takes place overseas, the technological advances and profits will follow. So should investors.
The Motley Fool April 22, 2008 Brian Orelli	Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth.
The Motley Fool August 19, 2008 Brian Orelli	Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic.
Pharmaceutical Executive October 1, 2011	Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool January 30, 2009 Brian Orelli	Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%.
The Motley Fool October 27, 2010 Travis Hoium	Amylin Pharmaceuticals Shares Popped: What You Need to Know Amylin Pharmaceuticals shares bounced 10% today on an upgrade from analysts at Leerink Swann.
IndustryWeek December 1, 2007 Jill Jusko	Hey Big Spender: By the Numbers A look at R & D spending in 2006.
Chemistry World October 1, 2012 Andrew Turley	Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years.
The Motley Fool November 8, 2011 Tim Beyers	Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals?
The Motley Fool April 30, 2011 Brian Orelli	No Long-Term Guidance? No Problem! Looking good, Merck.
The Motley Fool November 16, 2007 Brian Orelli	Weighing In on Amylin's Drug Combination Phase 2 results are good for Amylin Pharmaceuticals trial of a new weight-loss treatment, but it's the subsequent phase 3 trial that actually counts.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
The Motley Fool July 30, 2004 Chris Mallon	Adjusting for Innovation If research and development is an investment, why not treat it as such? While not necessarily cheap, tech companies don't appear quite so overvalued when you adjust for investment in innovation.
IEEE Spectrum December 2007 Hira & Ross	The R&D 100 A company's research budget tells you very little about its prospects.
The Motley Fool January 29, 2008 Brian Orelli	No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter.
The Motley Fool March 15, 2004 Ben McClure	More R&D, Please Big tech players up the research and development ante.
The Motley Fool August 27, 2008 Brian Orelli	Amylin Answers, Investors Panic Amylin Pharmaceuticals' conference call about side effects of its diabetes treatment, Byetta, doesn't have the desired effect.
IndustryWeek April 1, 2005 Patricia Panchak	Editor's Page -- Playing The R&D Blame Game The Bush Administration's 2006 budget short-changes industrial research and development. Industry executives and shareholders have also contributed to a slowing of spending on basic research.
HBS Working Knowledge March 20, 2006 Huston & Sakkab	P&G's New Innovation Model Procter & Gamble's assessment of its aging innovation process and the development of connect and develop.
The Motley Fool October 18, 2007 Brian Orelli	Amylin: Waiting on the Future Research and development costs drag down the drug developer's bottom line. Investors, take note.
The Motley Fool November 16, 2010 Selena Maranjian	Funding Tomorrow's Blockbusters Simply throwing money at R&D isn't always the best approach.
The Motley Fool October 17, 2007 Brian Orelli	FDA Warning Might Be a Buying Opportunity The 3%-4% drops in the stock prices of Amylin and Alkermes, Amylin's partner in the development of a sustained-release version of Byetta, could be a good buying opportunity for investors.
Chemistry World April 2007 Richard Barker	Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago.
The Motley Fool April 17, 2009 Brian Orelli	Cost-Cutting? Check. Increased Sales? Hmm ... Amylin has half the equation. Now it needs the other half.
Pharmaceutical Executive September 1, 2005 Parker & Amar	Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky.